{"filing":{"accession_number":"0001493152-26-030306","cik":"0000748592","ticker":"ERNAW","company_name":"Ernexa Therapeutics Inc.","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315226030306/form8-k.htm"},"events":[{"id":14281,"run_id":12705,"accession_number":"0001493152-26-030306","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Sandra Gurrola, Senior Vice President of Finance, delivered her notice of resignation effective July 3, 2026. The disclosure centers on her departure from the Company, which is material to investors as the CFO-level finance executive is a key officer. The resignation was not due to disagreement, and transition assistance is being arranged, but the principal event disclosed is the departure itself.","company_name":"Ernexa Therapeutics Inc.","ticker":"ERNAW","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11657,"accession_number":"0001493152-26-030306","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Sandra Gurrola, Senior Vice President of Finance, delivered her notice of resignation effective July 3, 2026. The disclosure centers on her departure from the Company, which is material to investors as the CFO-level finance executive is a key officer. The resignation was not due to disagreement, and transition assistance is being arranged, but the principal event disclosed is the departure itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:31:50.818297+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11657,"accession_number":"0001493152-26-030306","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Sandra Gurrola, Senior Vice President of Finance, delivered her notice of resignation effective July 3, 2026. The disclosure centers on her departure from the Company, which is material to investors as the CFO-level finance executive is a key officer. The resignation was not due to disagreement, and transition assistance is being arranged, but the principal event disclosed is the departure itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:31:50.818297+00:00","company_name":"Ernexa Therapeutics Inc.","ticker":"ERNAW","filing_date":"2026-06-26"}]}